MiR-205 is a potent promoter thet enhance motility in ovarian cancer cells

10^th Global Annual Oncologists Meeting

July 11-13, 2016 Cologne, Germany

Ke Niu and Yongxian Lu

First Affiliated Hospital, China

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

There are many molecular regulators in tumor EMT, such as miR-125a, the miR-200 family of microRNAs (miR-141, miR-200a, b, c, and miR-429), miR-34, miR-205, zinc finger E-box binding homeobox 1 (ZEB1) and zinc finger E-box binding homeobox. Our study investigated the clinical significance of microRNA-205 (miR-205) and zinc finger E-box binding homeobox 1 (ZEB1) in epithelial ovarian cancer (EOC) and the underlying mechanisms by which they are involved into tumorigenesis. In our research, we found miR-205 (P=0.0001) and ZEB1 mRNA (P b 0.0001) in clinical EOC tissues were significantly higher and lower than those in normal tissues, respectively. Interestingly, there was a negative correlation between miR-205 and ZEB1 mRNA expression in EOC tissues (P=0.01). Additionally, miR-205-upregulation and/or ZEB1-downregulation were significantly associated with high pathological grade and advanced clinical stage of EOC patients (all P b 0.05). Meantime, luciferase reporter assays identified ZEB1 as a direct target of miR-205 in EOC cells. Moreover, miR-205 blockage inhibited, whereas miR-205 mimics promoted the motility of EOC cells in vitro. Importantly, all the alterations of the above cellular phenotypes by blocking or enhancing of miR-205 could be alleviated by subsequent suppression or re-introduction of its target ZEB1, respectively. It is concluded that MiR-205, acting as an oncogenic miRNA, may promote the clinical progression of EOC patients and enhance the cellular motility in vitro by directly and negatively regulating ZEB1, providing a potential therapeutic strategy for suppression of EOC metastasis.

Biography :

Email: niuke304@163.com